New HIF-2 kidney cancer therapy more effective than current treatment, study shows

(UT Southwestern Medical Center) A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.